Nasus Pharma (NSRX) Equity Ratio (2024 - 2025)
Nasus Pharma (NSRX) reported Equity Ratio of 0.55 for Q4 2025, up 112.35% on a YoY basis from 0.26 in Q4 2024, and up 108.19% quarter-over-quarter from 6.75 in Q2 2025.
Nasus Pharma (NSRX) Equity Ratio (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Equity Ratio for 2 years, with the latest figure at 0.55 in Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio rose 112.35% year-over-year to 0.55; the trailing twelve-month figure through Dec 2025 stood at 0.55 (up 112.35% YoY), and the FY2025 full-year result was 0.55, up 112.35% from the prior year.
- Equity Ratio for Q4 2025 stood at 0.55, up from 6.75 in the prior quarter.
- The five-year high for Equity Ratio was 0.55 in Q4 2025, with the low at 6.75 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 0.27 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 0.40 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -0.05 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 0.36 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 0.10 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.42 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 0.43 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 0.23 |
| 10 | Nasus Pharma | 24.83 Mn | 20.55 Mn | - | 0.55 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.55 |
| Jun 30, 2025 | -6.75 |
| Dec 31, 2024 | -4.48 |